اثر بخشی درمان گروهی با رویکرد فراشناختی در کاهش افسردگی و سلامت روان بیماران مبتلا به مولتیپل اسکلروزیس
محورهای موضوعی :
1 -
کلید واژه: درمان فراشناختی, افسردگی, سلامت روان, ام اس,
چکیده مقاله :
مقدمه: مولتيپل اسكلروزيس (ام اس) به دلیل مزمن بودن ماهیت بیماری، نداشتن درمان قطعی و اختلالات روانی همراه آن می تواند اثر مخربی بر سلامت روان داشته باشد. پژوهش حاضر با هدف بررسی اثربخشی درمان فراشناختی گروهی بر افسردگی اساسی و سلامت روان بیماران مبتلا به ام اس صورت گرفت. روش: پژوهش حاضر از نوع نیمه تجربی از نوع پیش آزمون-پس آزمون همراه با گروه کنترل بود. تعداد30 آزمودنی با تشخیص بیماری‌ام اس و دارا بودن معیارهای ورود از بین افراد عضو انجمن ام اس به شیوه نمونه گیری در دسترس به طور تصادفی به دو گروه آزمایش (15 نفر) و کنترل (15 نفر) تقسیم شدند. پرسشنامه های افسردگی اساسی بک (BDI-II) و سلامت روان گلدبرگ توسط آزمودنی ها، پیش و پس از درمان تکمیل شد. گروه آزمایش، طی 8 جلسه 90 دقیقه‌ای تحت درمان با رویکرد فراشناختی به صورت گروهی قرار گرفتند. داده ها با استفاده از مدل آماری کوواریانس تک متغیری (آنکووا) تحلیل گردید. یافته‌ها: یافته های پژوهش نشان داد که بین میانگین نمرات افسردگی (04/0P=)، (53/3F=) و سلامت روان (02/0P=)، (48/4F=) پیش آزمون و پس آزمون گروه آزمایش و کنترل تفاوت معنی داری مشاهده شده است. نتیجه‌گیری: نتایج نشان می دهد که درمان فراشناختی به صورت گروهی بر کاهش افسردگی و بهبود سلامت روان بیماران ام اس مؤثر است. لذا به کارگیری این روش حمایتی، می تواند به عنوان یک راهکار مؤثر به منظور بهبود سلامت روان بیماران ام اس و توانمندسازی آنان بکار گرفته شود.
Introduction: Multiple sclerosis (M.S) can have a devastating effect on mental health due to the chronic nature of the disease, lack of definitive treatment and associated mental disorders. The aim of this study was to evaluate the effectiveness of group metacognitive therapy on major depression and mental health of patients with MS. Methods: The present study was a quasi-experimental pre test-post test with a control group. Thirty subjects were randomly divided into experimental (n = 15) and control (n = 15) groups with a diagnosis of MS and inclusion criteria among the members of the MS Association by available sampling method. Beck Depression Inventory (BDI-II) and Goldberg Mental Health Questionnaires were completed by subjects before and after treatment. The experimental group was treated as a group with metacognitive approaches for 8 sessions of 90 minutes. Data were analyzed using univariate covariance (ANCOVA) statistical model. Results: The findings showed that between the mean scores of depression (F = 3.53) (P = 0.40) and mental health (F = 48.4) (P = 0.02) pre-test and post-test Experiments of the experimental and control groups showed a significant difference. Conclusion: The results show that group metacognitive therapy is effective in reducing depression and improving the mental health of MS patients. Therefore, using this supportive method can be used as an effective strategy to improve the mental health of MS patients and empower them.
1. Chwastiak L, Ehde DM, Gibbonns LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. American Journal of Psychiatry. 2002; 159: 1862– 1868
2. Beiske AG, Pedersen ED, Czujko B, Myhr K‐M. Pain and sensory complaints in multiple sclerosis. European Journal of Neurology. 2004; 11: 479– 482
3. Figved N, Klevan G, Myhr K‐M, et al. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatrica Scandinavica. 2005; 112: 463– 468
4. Belbasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis, an umbrella review of systematic reviews and metaanalyses. Lancet Neurology. 2015; 14: 263–73
5. Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Multiple Sclerosis. 2017; 23: 1123–1136
6. Giovannoni G, Cutter G, Sormani MP, et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Multiple Sclerosis Related Disorders. 2017; 12: 70–78
7. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. Journal of Neurology. 2006; 253: 98–108.
8. Visschedijk MA, Collette EH, Polman CH, Pfennings LE, van der Ploeg HM. Development of A Cognitive Behavioral Group Intervention Programme for Patients With Multiple Sclerosis: Psycholgical Report. 2004; 95: 735-46
9. Sinclair VG, Scroggie J. Effects of a cognitive behavioral program for women with multiple sclerosis. Journal of Neuroscience Nursing. 2005; 37(5):249–57, 276
10. Buchanan RJ, Schiffer R, Wang S, Stuifbergen, A Chakravorty, B, Zhu L. et al. Demographic and disease characteristics of people with multiple sclerosis living in rural and urbanareas. International Journal of MS Care. 2006; 8: 89-97
11. Wells, A. fisher, p. Myers, S. Wheatley, J, J. Pateel, T. Brewin C.R. Metacognitive therapy in treatment-resistant depression: a platform trial. Behaviour Research and Therapy. 2012; Jun;50 (6):367-73. doi: 10.1016/j.brat.2012.02.004
12. Hoffart, A. Johnson, S. U. Nordahl, H. M. and Wells, A. Mechanisms of change in metacognitive and cognitive behavioral therapy for treatment-resistant anxiety:The role of metacognitive beliefs and coping strategies. Journal of Experimental Psychopathology. 2018; 9:2043808718787414. doi: 10.1177/204380871878 7414
13. Hall P, Crossley M, D’Arcy C. Executive function and survival in the context of chronic illness. Annals of Behavioral Medicine. 2010; 39:119–27
14. Wells, A. Metacognitive Therapy for Anxiety and Depression. New York, NY: The Guilford Press; 2009
15. Johnson, S. U. Hoffart, A. Nordahl, H. M. Ulvenes, P. G. Vrabel, K. and Wampold, B. E. Metacognition and cognition in inpatient MCT and CBT for comorbid anxiety disorders: a study of within-person effects. Journal of Counseling Psychology. 2018; 65, 86–97. doi: 10.1037/cou0000226
16. Johnson S U, Hoffart A. Metacognitive Therapy Versus Cognitive Behavioral Therapy: A Network Approach. Frontiers in Psychology, 2018; https://doi.org/10.3389/fpsyg.2018.02382
17. Roelofs, J. Papageorgiou, C. Gerbera, R. Huibersa, M. Peeters, F. Arntza, A. On the links between self-discrepancies, rumination, metacognitions, and symptoms of depression in undergraduates. Behavior Research and Therapy. 2006; 45, 1295–1305
18. Wells, A. Fisher, P.L. Myers, S. Wheatley, J. Patel, T. & Brewin, C. Metacognitive therapy in treatment-resistant depression: A platform trial. Behaviour Research and Therapy. 2012; 50 (6), 367-373
19. First, MB. spritzer, L. Gibbon, M. Williams, JBW. Structural clinical interview for DSM-IV-TR axis I disorder, clinical version, and patient edition. (SCIDCV).Washington, DC: American psychiatric press. 1996
20. First, M. Spitzer, R. Gibbon, M. & Williams, J.B. Structured Clinical Interview for DSM-IV Axis I Disorders (clinician version) SCID-I administration booklet. Washington DC, American Psychiatric Association. 1997
21. Sharifi V, Assadi S M, Mohammadi M R, E, et al. Reliability of the Persian version of the structured interview Diagnostic for (SCID) DSM-IV.2004; Advances in Cognitive Sciences. 6 (2), 10-22 (in Persian)
22. Steer R A, Ranieri W F, Beck A T, Clark D A. Further evidence for the validity of the beck anxiety inventory with psychiatric outpatients. Journal of Anxiety Disorders. 1993; 7 195–205. 10.1016/0887-6185(93)90002-3
23. Ghasemzadeh H. Psychometric properties of a Persian-language version of the beck depression inventory 2nd Ed: BDI II-persian. Depression and Anexiety. 2005; 21: 185-92. [In Persian]
24. Taghavi M R. Evaluation of validity and reliability of general health questionnaire. Journal of Psychology, 20, 381-395. [In Persian].
25. Papageorgiou, C, Wells A. An empirical test of a clinical Metacognitive model of rumination and depression. Cognitive Therapy and Research. 2003; 27: 261-273
26. De Jong – Meyer, R. Beck, B. and Riede, K. Relationships between rumination worry, intolerance of uncertainty and metacognitive beliefs.Personality and Individual Differences. 2009; 46: 547 – 551.
27. Corcoran K, Segal Z, Meta-Cognition in Depressive and Anxiety Disorders: Current Directions. International Journal of Cognitive Therapy,2008; 1(1): 33- 44.
28. Callesen P, Jensen A. B, Wells A. Metacognitive therapy in recurrent depression: a case replication series in Denmark. Scandinavian Journal of Psychology. 2015; 55 60–64. 10.1111/sjop.12089
29. Bevan D, Wittkowski A, Wells A. A multiple-baseline study of the effects associated with metacognitive therapy in postpartum depression. J. Midwifery Womens Health. 2013; 58 69–75. 10.1111/j.1542-2011.2012.00255.
30. Groves S J, Porter R J, Jordan J, Knight R, Carter J D, McIntosh V V W, et al. Changes in neuropsychological function after treatment with metacognitive therapy or cognitive behavior therapy for depression. Depression and Anxiety. 2015; 326 437–444. 10.1002/da.22341
31. Hjemdal O. Hagen R. Solem S. Nordahl H. Kennair L. E. O. Ryum T. et al. Metacognitive therapy in major depression: an open trial of comorbid cases. Cogn. Behav. Pract. 2016; 0.1016/j.cbpra.2016.06.006
32. Normann N. van Emmerik A. A. P. Morina N. (2014). The efficacy of metacognitive therapy for anxiety and depression: a meta-analytic review. Depress. Anxiety 31 402–411. 10.1002/da.22273
33. Segal, ZV. Williams, JMG. Teasdale, JD. (2002). Mindfulness-based cognitive therapy for depression: A new approach to preventing relapse.New Yourk: Guilford press.
34. Corcoran, K. Segal, z. Meta-Cognition in Depressive and Anxiety Disorders: Current Directions. International Journal of Cognitive Therapy, 2008; 1(1): 33- 44.
35. Wells A. Emotional Disorders and Metacognition: A Practical Manual and Conceptual Guide. Chichester: Wiley. 2000
